482 “Another Method for Thawing Hematopoietic STEM CELLS and Its Impact in the Recovery of the Transplanted Hematological Patient

Track: Contributed Abstracts
Saturday, February 16, 2013, 6:45 PM-7:45 PM
Hall 1 (Salt Palace Convention Center)
Consuelo Mancias-Guerra Sr., MD Hematologist , Hematology Service, University Hospital of Monterrey, Monterrey, Mexico
Sagrario Lisete Valdés-Burnes Jr. , Hematology Service, University Hospital of Monterrey, Monterrey, Mexico
Oscar Gonzalez-Llano Sr., MD Hematologist , Hematology Service, University Hospital of Monterrey, Monterrey, Mexico
Guillermo Cayetano Aguirre-Fernandez Jr. , Hematology Service, University Hospital of Monterrey, Monterrey, Mexico
Laura Villarreal-Martinez Jr., MD Hematologist , Hematology Service, University Hospital of Monterrey, Monterrey, Mexico
Olga Cantu-Rodriguez Sr., MD Hematologist , Hematology Service, University Hospital of Monterrey, Monterrey, Mexico
Cesar Homero Gutierrez-Aguirre Sr., MD Hematologist , Hematology Service, University Hospital of Monterrey, Monterrey, Mexico
David Gomez-Almaguer Sr., MD Hematologist , Hematology Service, University Hospital of Monterrey, Monterrey, Mexico

Introduction

There are several hematopoietic-stem cells (HSCs) thawing methods for bone marrow reconstitution. They intend to avoid cell death and patient's side effects due to the dimethyl sulfoxide (DMSO). We propose another thawing method that diminishes cell death and therefore a more rapid hematological recovery.

Material and Methods

The standard thawing-removing DMSO method for cord blood units was described by Rubinstein in 1995 (method 1). Ours (method 2) pretend to increase more than 10 fold the dilution of cryopreserved HSCs in the standard washing solution (5% albumin + dextran 40). Methods 1 and 2 were compared to determine viability by means of total-nucleated-cell (TNC) count by trypan blue and flow cytometry at the time of collection, cryopreservation, thawing, and after removing the DMSO, as well as the patient's day of engraftment.

Results

Results are shown in Table 1 and 2.

Conclusions

A greater dilution of cryopreserved HSCs in the washing solution, as a new thawing method, may decrease cell death; therefore a greater number of HSCs will be infused to the patient. Studies with a larger number of thawing procedures are needed to make this assertion.

Table 1. Patient's demographic data.

Global

Method 1

Method  2

P

Total (n)

26

13

13

Transplant (n)

      Autologous

      Allogeneic

12

14

5

8

7

6

.43

Receptor age (years)

       Median (range)

26 (3-56)

27 (5-55)

25 (3-56)

.75

Figure 1. Viability loss

Figure 2. Neutrophil engrafment

Figure 3. Platelel engrafment

Table 2. Overall results in the study.

Global

Rubinstein's Method

New Method

P

Viability before thawing.

Mean (SD)

97.28% (6.55)

99.01% (1.08)

95.56% (9.04)

.30

Viability after thawing.

Mean (SD)

78.92% (11.69)

75.46% (12.5)

82.39% (10.12)

.15

Viability loss.

Mean (SD)

18.36% (12.11)

23.55% (12.74)

13.18% (9.21)

.02

Engrafment days

>20,000 Platelets.

Median (range)

11 (6-23)

11 (6-23)

11 (7-19)

.60

Engrafment days

>500 Neutrophils.

Median (range)

13.5 (6-28)

13 (6-28)

14 (9-17)

.30